Polycystic Kidney Disease Panel

New York
Approved


Genes

GANAB, HNF1B, PKD1, PKD2, PKHD1, PRKCSH, TSC2

Conditions

  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease
  • Polycystic Kidney Disease

Clinical Utility

  • Molecular confirmation of a clinical diagnosis
  • Development of appropriate evaluation and management plan
  • Evaluation of family members as possible donors for kidney transplantation
  • Testing of at-risk relatives for specific known variant(s) previously identified in an affected family member
  • Genetic counseling, especially recurrence risk

Lab Method

  • Next-Gen Sequencing
  • Deletion/Duplication Analysis

Important Information

Test is designed to identify a contiguous gene deletion involving PKD1 and TSC2, not to identify sequencing and exon-level copy number variants of TSC2. Sequencing of the PKD1 gene is challenging due to high homology with six known pseudogenes (exons 1-33). Our NGS assay is specifically designed to provide superior mapping quality and uniform coverage across the coding region of PKD1, enabling robust detection of variants including indels. For mapping quality of >20, 99.7% of the targeted nucleotides have a mean coverage of 264 reads; even at a mapping quality of >40, mean coverage is 254x. PKD1 variants are confirmed by long-range, nested PCR and capillary sequencing. For Deletion/Duplication analysis, Multiplex Ligaton-Dependent Probe Amplification (MLPA) is performed.

Test Code

TG22

CPT Codes*

81404x1, 81405x1, 81406x2, 81407x1, 81408x1, 81479x1

ABN Required

No

Turnaround Time**

4-6 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs | Extracted DNA

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.